Assessing the Ontogeny of P-glycoprotein Expression in Blood of Pediatric Leukemic Patients
Assessing the Ontogeny of P-glycoprotein Expression in Blood of Pediatric Leukemic Patients
Determine P-glycoprotein expression in blood samples of Acute Lymphocytic leukemia (ALL) pediatric patients receiving MTX treatment and trace its ontogeny and compare it with its expression in pediatric healthy subjects. In addition, to determine the correlation of P-glycoprotein expression and Methotrexate concentration at steady state.
The 20 leukemic patients will be classified into three age groups according to the ages that will be available at the time of sample collection.
Blood Samples will be obtained from healthy pediatric subjects of the same ages of the diseased group subjects (Samples will be obtained from subjects from a primary care center during their routine blood analysis excluding patients of chronic diseases, patients receiving any medications, and patients of impaired kidney or liver functions).
P-glycoprotein expression will be estimated in all samples using Permeability glycoprotein (P-gp), ELISA Kit, and its expression will be traced with development from the youngest till the oldest age available, this will also be compared with normal healthy pediatric subjects.
Inclusion Criteria:
Exclusion Criteria:
Severe renal impairment (eGFR< 30 mL/min/1.73 m2 at screening)